Combination treatment for newly diagnosed high-grade glioma
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed high-grade glioma (a fast-growing brain or spinal cord tumor) that has been confirmed by biopsy or surgery.
- You must not have received any previous treatment for the tumor, such as chemotherapy, radiation, or other drugs, except surgery.
- You must have had surgery to remove as much of the tumor as safely possible (or at least a biopsy for certain tumors).
- Your age must be within the study range: 3 to 25 years for most tumors, or 3 to 39 years for certain types.
- You must have enough tumor tissue (from surgery) available for research testing.
- Your kidneys, liver, and blood counts must be within acceptable limits, and you must be generally well enough (able to be up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial tests a combination of two drugs (temozolomide and dexbrompheniramine) to treat high-grade gliomas that have come back after standard treatment. The goal is to see if this combination can help control the tumor or slow its growth.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.